OraSure Announces Fourth Quarter and Full-Year 2011 Financial Results
Company Reports Record Quarterly Revenues
Financial Highlights
- Consolidated revenues were
$23.7 million for the fourth quarter of 2011, a 26% increase from the comparable quarter of 2010. Revenues for the current quarter included$19.5 million fromOraSure operations and$4.2 million from DNA Genotek ("DNAG") operations. The Company completed its acquisition of DNAG onAugust 17, 2011 . - Consolidated revenues were
$81.9 million for the full-year 2011, a 9% increase from 2010. Full-year revenues included$75.7 million fromOraSure operations and$6.2 million from DNAG operations. - Consolidated net income for the fourth quarter of 2011 was
$115,000 , or$0.00 per share, which compares to a net loss of$1.0 million , or$0.02 per share, for the fourth quarter of 2010. The current quarter net income includes a net loss of$195,000 , and an income tax benefit of$553,000 , both attributable to DNAG. - Consolidated net loss for the full-year 2011 totaled
$8.8 million , or$0.19 per share, which compares to a net loss of$3.5 million , or$0.08 per share, for 2010. The current year loss includes a$693,000 net loss attributable to DNAG, which reflects$2.1 million in non-cash charges associated with amortization of intangible assets and certain purchase accounting inventory adjustments related to the acquisition, partially offset by$869,000 in related tax benefits. The 2011 consolidated net loss also includes approximately$2.6 million of acquisition-related transaction costs incurred byOraSure and$7.9 million of clinical trial spending related to the Company's OraQuick® HIV over-the-counter ("OTC") product.
"During the fourth quarter of 2011, we achieved two major milestones in our principal clinical development programs," said
Financial Results
Excluding DNAG sales, product revenues for the quarter and year ended
The Company reported consolidated net income of
The purchase accounting inventory adjustment is related to the write up of DNAG's finished goods inventory to fair market value as of the acquisition date. For the quarter and year ended
The Company reported a consolidated net loss of
Consolidated gross margin for the three months ended
Consolidated operating expenses increased to
For the quarter and year ended
Cash, cash equivalents and short-term investments totaled
First Quarter 2012 Outlook
The Company expects total consolidated revenues for the first quarter of 2012 to range from
Financial Data
Condensed Consolidated Financial Data | ||||
(In thousands, except per-share data) | ||||
Unaudited | ||||
Three months ended | Year ended | |||
December 31, | December 31, | |||
2011 | 2010 | 2011 | 2010 | |
Results of Operations | ||||
Revenues | $ 23,690 | $ 18,817 | $ 81,881 | $ 75,015 |
Cost of products sold | 9,094 | 6,853 | 30,164 | 27,656 |
Gross profit | 14,596 | 11,964 | 51,717 | 47,359 |
Operating expenses: | ||||
Research and development | 3,297 | 4,048 | 18,407 | 13,192 |
Sales and marketing | 6,357 | 4,830 | 22,383 | 20,727 |
General and administrative | 5,222 | 4,018 | 20,325 | 16,794 |
Total operating expenses | 14,876 | 12,896 | 61,115 | 50,713 |
Operating loss | (280) | (932) | (9,398) | (3,354) |
Other expense | (158) | (91) | (312) | (143) |
Loss before income taxes | (438) | (1,023) | (9,710) | (3,497) |
Income tax benefit | (553) | -- | (869) | -- |
Net income (loss) | $ 115 | $ (1,023) | $ (8,841) | $ (3,497) |
Earnings (loss) per share: | ||||
Basic and Diluted | $ -- | $ (0.02) | $ (0.19) | $ (0.08) |
Weighted average shares: | ||||
Basic | 47,264 | 46,221 | 46,908 | 46,187 |
Diluted | 48,893 | 46,221 | 46,908 | 46,187 |
Three Months Ended December 31, | |||||
Dollars | Percentage of Total Revenues | ||||
Market | 2011 | 2010 | % Change |
2011 | 2010 |
Infectious disease testing | $ 11,592 | $ 11,437 | 1% | 49% | 61% |
Substance abuse testing | 3,487 | 2,886 | 21 | 15 | 15 |
Cryosurgical systems | 3,139 | 2,844 | 10 | 13 | 15 |
Molecular collection systems | 4,194 | -- | 100 | 17 | -- |
Insurance risk assessment | 1,087 | 1,355 | (20) | 5 | 7 |
Product revenues | 23,499 | 18,522 | 27 | 99 | 98 |
Licensing and product development | 191 | 295 | (35) | 1 | 2 |
Total revenues | $ 23,690 | $ 18,817 | 26% | 100% | 100% |
Year Ended December 31, | |||||
Dollars | Percentage of Total Revenues | ||||
Market | 2011 | 2010 | % Change |
2011 | 2010 |
Infectious disease testing | $ 44,691 | $ 41,738 | 7% | 55% | 55% |
Substance abuse testing | 12,498 | 11,671 | 7 | 15 | 16 |
Cryosurgical systems | 12,046 | 11,965 | 1 | 15 | 16 |
Molecular collection systems | 6,216 | -- | 100 | 8 | -- |
Insurance risk assessment | 5,232 | 5,825 | (10) | 6 | 8 |
Product revenues | 80,683 | 71,199 | 13 | 99 | 95 |
Licensing and product development | 1,198 | 3,816 | (69) | 1 | 5 |
Total revenues | $ 81,881 | $ 75,015 | 9% | 100% | 100% |
Three Months Ended | Year Ended | |||||
December 31, | December 31, | |||||
OraQuick(R) Revenues | 2011 | 2010 | % Change |
2011 | 2010 | % Change |
Domestic HIV | $ 9,775 | $ 10,093 | (3)% | $38,722 | $ 38,172 | 1% |
International HIV | 721 | 766 | (6) | 3,011 | 1,800 | 67 |
Domestic HCV | 426 | 44 | 868 | 890 | 46 | 1,835 |
International HCV | 387 | 63 | 514 | 672 | 119 | 465 |
Total OraQuick(R) revenues | $ 11,309 | $ 10,966 | 3% | $43,295 | $ 40,137 | 8% |
Three Months Ended | Year Ended | |||||
December 31, | December 31, | |||||
Intercept(R) Revenues | 2011 | 2010 | % Change |
2011 | 2010 | % Change |
Domestic | $ 2,096 | $ 1,883 | 11% | $ 8,004 | $ 7,274 | 10% |
International | 439 | 454 | (3) | 1,912 | 1,976 | (3) |
Total Intercept(R) revenues | $ 2,535 | $ 2,337 | 8% | $ 9,916 | $ 9,250 | 7% |
Three Months Ended | Year Ended | |||||
December 31, | December 31, | |||||
Cryosurgical Systems Revenues | 2011 | 2010 | % Change |
2011 | 2010 | % Change |
Professional domestic | $ 1,678 | $ 1,492 | 12% | $ 6,775 | $ 5,967 | 14% |
Professional international | 412 | 520 | (21) | 1,400 | 1,385 | 1 |
Over-the-Counter | 1,049 | 832 | 26 | 3,871 | 4,613 | (16) |
Total cryosurgical systems revenues | $ 3,139 | $ 2,844 | 10% | $ 12,046 | $ 11,965 | 1% |
Consolidated Balance Sheets (Unaudited) | December 31, 2011 | December 31, 2010 |
Assets | ||
Cash, cash equivalents and short-term investments |
$ 23,878 | $ 75,738 |
Accounts receivable, net | 17,159 | 12,471 |
Inventories | 9,621 | 7,346 |
Other current assets | 2,178 | 1,930 |
Property and equipment, net | 19,855 | 19,611 |
Intangible assets, net | 30,383 | 4,807 |
Goodwill | 24,740 | -- |
Other non-current assets | 47 | 617 |
Total assets | $ 127,861 | $ 122,520 |
Liabilities and Stockholders' Equity | ||
Current portion of long-term debt | $ 7,292 | $ 7,791 |
Accounts payable | 4,142 | 2,899 |
Accrued expenses | 10,542 | 8,987 |
Deferred income taxes, net | 5,636 | -- |
Stockholders' equity | 100,249 | 102,843 |
Total liabilities and stockholders' equity | $ 127,861 | $ 122,520 |
Year ended | ||
December 31, | ||
Additional Financial Data (Unaudited) | 2011 | 2010 |
Capital expenditures | $ 2,505 | $ 2,106 |
Acquisition of DNA Genotek, Inc. (net of cash acquired) |
$ 49,730 | $ -- |
Depreciation and amortization | $ 4,915 | $ 3,012 |
Stock based compensation | $ 4,101 | $ 3,229 |
Cash provided by (used in) operating activities | $ (2,991) | $ 3,887 |
Accounts receivable -- days sales outstanding |
68 days | 61 days |
Conference Call
The Company will host a conference call and audio webcast to discuss the Company's 2011 fourth quarter and full-year financial results, business developments and first quarter 2012 financial guidance, beginning today at
In order to listen to the conference call, please either dial 877-348-9357 (Domestic) or 970-315-0488 (International) and reference Conference ID #44923763, or go to
About
The
Important Information
This press release contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through an internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts or minimum purchase requirements for the Company's products; impact of replacing distributors and success of direct sales efforts; inventory levels at distributors and other customers; ability to integrate and realize the full benefits of the Company's acquisition of DNA Genotek; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of the economic downturn, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance, extended shelf life or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical product components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to refinance outstanding debt under expiring credit facilities on acceptable terms or at all; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company's Securities and Exchange Commission filings, including its registration statements, Annual Report on Form 10-K for the year ended
CONTACT:Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com
Image: company logo